Gainor et al. discovered that low response rates to PD-1/PD-L1 inhibitor therapy in patients with NSCLC were associated with epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase rearrangements (ALK) [27]. This evidence concerns the gene ALK and non-small cell lung carcinoma.